ArticleDiscover oncology2025
AKR1B10 as a novel prognostic biomarker linking methylation and immune escape in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between unilateral third molar elongation, temporomandibular joint space asymmetry, and posterior tooth wear: a CBCT study.BMC oral health · 2026Article
- CXCL1 as a novel prognostic biomarker and immune regulator in colon adenocarcinoma.Discover oncology · 2026Article
- Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Frontiers in immunology · 2026Review
- Predictive value of preoperative serum thyroglobulin and anti-thyroglobulin antibodies for central compartment lymph node metastasis in cN0 papillary thyroid carcinoma.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveLiver cancer continues to be a significant challenge among malignancies today. Hepatocellular carcinoma is one of the cancers that exhibits a marked upregulation of AKR1B10, an enzyme involved in cellular metabolism. The advancement of HCC treatment indicates that immunotherapy and molecular targeted therapies exhibit potential efficacy. However, the primary targets for liver cancer are not yet well-defined. Therefore, this study investigates the mechanism of AKR1B10 to assess its potential as a prognostic biomarker in liver cancer.
methodsGenetic changes, genomic expression, and methylation analyses were sourced from the TCGA, CPTAC, UALCAN, HPA, cBioPortal, and MethSurv databases. The gene expression is validated by qPCR. The diagnostic and prognostic significance of AKR1B10 in LIHC was assessed using data from ROC analysis and KM-plotter. Functional analyses were performed utilizing the GeneMANIA and STRING databases, along with gene-gene and PPI networks, GO terms, and KEGG pathway analyses. The relationship with immune escape was explored through analyses conducted using the TIMER, TISIDB, and GEPIA databases. Additionally, GSCALite was utilized to analyze drug sensitivity in relation to AKR1B10 expression in tumors.
resultsAKR1B10 expression was found to be statistically significantly higher in HCC cells than in their corresponding normal control cells, according to qPCR analysis. ROC analysis identified AKR1B10 as a novel biomarker for diagnosing LIHC. Univariate Cox regression analysis indicated AKR1B10 association with poor LIHC patient prognosis. Integrative analyses, including genetic alterations, gene-gene interactions, PPI networks, and enrichment analyses, support a novel role for AKR1B10 in HCC progression. Hypermethylation of AKR1B10 at various CpG sites was associated with improved or diminished OS in LIHC, and AKR1B10 exhibited a robust correlation with the top 25 genes that were either hypo- or hypermethylated. Furthermore, the findings indicated that AKR1B10 may affect the TME and is associated with immune checkpoints.
conclusionsThis study’s comprehensive analyses indicate AKR1B10 as a novel biomarker for LIHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.